Cited 25 times in
Targeting Integrin-Linked Kinase Suppresses Invasion and Metastasis through Downregulation of Epithelial-to-Mesenchymal Transition in Renal Cell Carcinoma
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 한경석 | - |
dc.contributor.author | 홍성준 | - |
dc.date.accessioned | 2016-02-04T12:02:18Z | - |
dc.date.available | 2016-02-04T12:02:18Z | - |
dc.date.issued | 2015 | - |
dc.identifier.issn | 1535-7163 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/141752 | - |
dc.description.abstract | Renal cell carcinoma (RCC) is the most common malignancy in the kidney. Antiangiogenic targeted therapies inhibit the progression of RCC, but have limited impacts on invasion or metastasis of tumor cells. Integrin-linked kinase (ILK) is a serine/threonine kinase implicated in the regulation of cell growth/survival, cell-cycle progression, epithelial-mesenchymal transition (EMT), invasion/migration, and angiogenesis. However, the role of ILK in RCC has not been evaluated. We investigated the role of ILK on cancer progression and metastasis and the therapeutic potential of ILK inhibition in RCC. Our investigation reveals that ILK is expressed at a low level in normal cells and low-stage RCC cells and is highly expressed in advanced and metastatic cells. Caki-1, a metastatic RCC cell line, showed higher expression of molecular EMT markers, including Snail and Zeb1, but decreased activity of GSK3β. Knockdown of ILK using small interference (si)-ILK minimally inhibited tumor proliferation and cell-cycle progression was not significantly affected. However, ILK knockdown suppressed the formation of stress fibers and focal adhesions and impeded phenotypic EMT markers, including cell migration and invasion, in Caki-1 and UMRC-3 cells. Finally, in vivo knockdown of ILK suppressed the progression, invasion, and metastasis of primary RCC in nude mice by downregulation of EMT markers (Snail, Zeb1, vimentin, and E-cadherin). Our results show that ILK may be essential for invasion and metastasis in RCC and regulates vimentin and E-cadherin expression by regulating the EMT-related transcription factors Snail and Zeb1. These results suggest that ILK may be a potential target in RCC. | - |
dc.description.statementOfResponsibility | open | - |
dc.format.extent | 1024~1034 | - |
dc.relation.isPartOf | MOLECULAR CANCER THERAPEUTICS | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Animals | - |
dc.subject.MESH | Biomarkers | - |
dc.subject.MESH | Carcinoma, Renal Cell/genetics* | - |
dc.subject.MESH | Carcinoma, Renal Cell/metabolism | - |
dc.subject.MESH | Carcinoma, Renal Cell/pathology* | - |
dc.subject.MESH | Cell Line, Tumor | - |
dc.subject.MESH | Cell Movement | - |
dc.subject.MESH | Cell Survival/genetics | - |
dc.subject.MESH | Disease Models, Animal | - |
dc.subject.MESH | Down-Regulation | - |
dc.subject.MESH | Epithelial-Mesenchymal Transition/genetics* | - |
dc.subject.MESH | Gene Expression | - |
dc.subject.MESH | Gene Knockdown Techniques | - |
dc.subject.MESH | Heterografts | - |
dc.subject.MESH | Homeodomain Proteins/genetics | - |
dc.subject.MESH | Homeodomain Proteins/metabolism | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Mice | - |
dc.subject.MESH | Neoplasm Staging | - |
dc.subject.MESH | Phenotype | - |
dc.subject.MESH | Protein-Serine-Threonine Kinases/genetics* | - |
dc.subject.MESH | Protein-Serine-Threonine Kinases/metabolism | - |
dc.subject.MESH | RNA Interference | - |
dc.subject.MESH | RNA, Small Interfering/genetics | - |
dc.subject.MESH | Snail Family Transcription Factors | - |
dc.subject.MESH | Transcription Factors/genetics | - |
dc.subject.MESH | Transcription Factors/metabolism | - |
dc.subject.MESH | Zinc Finger E-box-Binding Homeobox 1 | - |
dc.title | Targeting Integrin-Linked Kinase Suppresses Invasion and Metastasis through Downregulation of Epithelial-to-Mesenchymal Transition in Renal Cell Carcinoma | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Urology (비뇨기과학) | - |
dc.contributor.googleauthor | Kyung Seok Han | - |
dc.contributor.googleauthor | Na Li | - |
dc.contributor.googleauthor | Peter A. Raven | - |
dc.contributor.googleauthor | Ladan Fazli | - |
dc.contributor.googleauthor | Susan Ettinger | - |
dc.contributor.googleauthor | Sung Joon Hong | - |
dc.contributor.googleauthor | Martin E. Gleave | - |
dc.contributor.googleauthor | Alan I. So | - |
dc.identifier.doi | 10.1158/1535-7163.MCT-14-0771 | - |
dc.admin.author | false | - |
dc.admin.mapping | false | - |
dc.contributor.localId | A04264 | - |
dc.contributor.localId | A04402 | - |
dc.relation.journalcode | J02254 | - |
dc.identifier.eissn | 1538-8514 | - |
dc.identifier.pmid | 25657336 | - |
dc.identifier.url | http://mct.aacrjournals.org/content/14/4/1024.abstract | - |
dc.contributor.alternativeName | Han, Kyung Seok | - |
dc.contributor.alternativeName | Hong, Sung Joon | - |
dc.contributor.affiliatedAuthor | Han, Kyung Seok | - |
dc.contributor.affiliatedAuthor | Hong, Sung Joon | - |
dc.rights.accessRights | not free | - |
dc.citation.volume | 14 | - |
dc.citation.number | 4 | - |
dc.citation.startPage | 1024 | - |
dc.citation.endPage | 1034 | - |
dc.identifier.bibliographicCitation | MOLECULAR CANCER THERAPEUTICS, Vol.14(4) : 1024-1034, 2015 | - |
dc.identifier.rimsid | 30864 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.